Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1T3KQ)

Drug Name
AMG-714 Drug Info
Indication
Disease Entry ICD 11 Status REF
Coeliac disease DA95 Phase 2 [1]
Rheumatoid arthritis FA20 Discontinued in Phase 1 [2]
Cross-matching ID
TTD Drug ID
DM1T3KQ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Interleukin-15 (IL15)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BNZ-1 DM8JQZC Cutaneous T-cell lymphoma 2B01 Phase 2 [3]
SAR445877 DM91KZL Aggressive cancer 2A00-2F9Z Phase 2 [4]
N-803 DM4ZN8M Human immunodeficiency virus infection 1C62 Phase 1 [5]
PF-07209960 DM1W90B Aggressive cancer 2A00-2F9Z Phase 1 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-15 (IL15) TTJFA35 IL15_HUMAN Not Available [2]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
3 Clinical pipeline report, company report or official report of Bioniz Therapeutics.
4 Clinical pipeline report, company report or official report of Sanofi
5 The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. PLoS Pathog. 2020 Mar 12;16(3):e1008339.
6 ClinicalTrials.gov (NCT04628780) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.